Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study

2019/01/25 by McKay, Kyla A., Tremlett, Helen, Patten, Scott B. +5
#Multiple sclerosis #adherence #beta-interferon #glatiramer acetate #health behavior #immunomodulatory therapy

paper · doi:10.11575/prism/35780

Abstract

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded by the Canadian Institutes of Health Research (CIHR CBG 101829), the Rx&D Health Research Foundation and by a Don Paty Career Development Award from the MS Society of Canada (to RAM).

Related

• The Prevalence of Comorbidities and Their Association With Disability Progression in Individuals With Multiple Sclerosis: A Study From Brazil
• Comparing the Effectiveness of Treatment based on Acceptance and Commitment and Reality Therapy on Adherence to Treatment in Women with Multiple sclerosis
• Development of a core outcome set for the trials of complementary therapies in people with multiple sclerosis: international survey and consensus meetings
• Investigating the Impact of Polypharmacy and Anticholinergic Medication Burden on Objective Cognitive Performance in Adults With Multiple Sclerosis
• PANORAMA: A 2021 Clinician Survey of Treatment Approaches for People With New Diagnoses of Relapsing-Remitting Multiple Sclerosis in the United Kingdom